THE

FASTER

WE MOVE

MEDSIR ATTENDS MANY GLOBAL SCIENTIFIC CONGRESSES THROUGHOUT THE YEAR. WE LOOK FORWARD TO MEETING YOU!

MEDSIR ATTENDS MANY GLOBAL SCIENTIFIC CONGRESSES THROUGHOUT THE YEAR. WE LOOK FORWARD TO MEETING YOU!

PHENOMENAL Study reach a New Milestone!

December 19, 2019

This last September (2019), the 23rd patient in the Phenomenal Study was included in the trial. We have reached a new milestone, the Stage I have recruited 23 evaluable patients. An interim analysis...

A New Trial On Board: The ORPHEUS Study

December 2, 2019

MedSIR will soon begin the ORPHEUS study “A Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile Squamous...

REVERT Study Poster Presentation at SABCS 2019

December 13, 2019

REVERT study (design, background, primary, a secondary endpoint, trial enrollment) has been scheduled for presentation in a Poster Session at SABCS 2019 on San Antonio (Texas, USA)...

Last Patient Last Visit for Interim Analysis in PHERGain Study

November 21, 2019

A new milestone of PHERGain study-Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy-has been achieved...

The Beginning of the LUZERN Study

December 5, 2019

Last 11th November 2019, it was submitted the LUZERN study to AEMPS and CEIm with the participation of 10 different sites in Spain. Overall, we expect to recruit a total of 23 patients. Sites activation is...

Liquid biopsy and ctDNA: the winner tandem

November 13, 2019

Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Recent advances in science...